

## **REMARKS**

### **Claims**

Claims 74–78 are currently under examination with claims 1–73 and 79 being cancelled without prejudice or disclaimer. Claims 80–90 are added by this paper.

### **Claim amendments**

Previously withdrawn claims are now cancelled as requested by the Examiner. Applicants reserve the right to pursue the subject matter of the withdrawn claims in a separate divisional application.

Independent claim 74 incorporates all the elements of previously presented claims 56, 57, 59, and 73, which are now cancelled. Support for the structural and functional components of the antibody molecules claimed therein can be found in, for example, page 3, lines 23–30 of the originally filed specification. Sub-claim (v) of claim 74 is supported by the disclosure contained in, for example, page 39, lines 25–32. Dependent claims 72 and 75–77 have been amended to depend on independent claim 74.

New claims 80–85 are supported by the disclosure contained in Applicants' specification, as originally filed. Support for new claims 80–85 can be found in, for example, the paragraphs bridging pages 2–4 of the instant specification and the disclosure contained in the Examples. Support for new claims 86–87 can be found in, for example, the paragraph bridging page 21 and 22. Support for new claims 88–90, along with amendment of claim 75 can be found in, for example, the paragraphs bridging page 23, line 1 to page 24, line 15 of the specification. Finally, new claim 91 corresponds to the combination of claims 74–78.

It is respectfully submitted that the claim amendments do not raise new matter.

### **Sequence disclosure**

An updated sequence disclosure and the corresponding amendment of the specification to recite the sequence identifier numbers (SEQ ID NO) of the disclosed molecules were filed on July 13, 2007. The Patent Application Information Retrieval (PAIR) database indicates that the amendments were entered on August 13, 2007. Withdrawal of the objection is respectfully requested.

In view of the above-mentioned arguments and amendments, it is respectfully submitted that the claims in the application are in condition for allowance. However, if the Examiner has any questions or comments, he is cordially invited to telephone the undersigned at the number below.

The Commissioner is hereby authorized to charge any fees associated with this response to Deposit Account No. 13-3402.

Respectfully submitted,

/Brion P. Heaney/

Brion P. Heaney, Reg. No. 32,542

Attorney for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: **MERCK-2309**

Date: September 27, 2007